Bob DutcherChairman, President and CEO

Jules FisherCFO & Vice President, Finance

September 2007

Certain statements in this slide presentation constitute “forward-looking statements”within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of these statements relate to estimated future revenue, gross margins and earnings per share, estimated market potential and the continuing impact from the results of the AiMI trial. These statements are based on our current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements such as the effectiveness of our sales and marketing efforts in re-establishing coronary product usage, our ability to secure favorable distribution partnerships, our ability to effectively introduce and market new products, success in obtaining new regulatory approvals and clearances, impact of competition and our ability to generate suitable clinical registry data to support growing use of the AngioJet System and our other endovascular products. A discussion of these and other factors that could impact the Company’s future results are set forth in the cautionary statements included in Exhibit 99 to the Company’s Form 10K for the year ended July 31, 2006, filed with the Securities and Exchange Commission.

Forward-Looking Statements

Public: NASDAQ Global Select Market: POSSRussell Micro-cap IndexS&P Small Cap 600

Stage: Profitable Small-cap

Business: Medical Devices

Markets: Endovascular Mechanical Thrombectomy, Embolic Protection/Temporary Occlusion, Access Site Hemostasis

Location: Minneapolis, Minnesota

Employees: 288, including 87 direct U.S. sales

Possis Facts

U.S. Sales Structure

• 9 U.S. Regional Sales Managers

• 34 Sales Representatives

• 44 Clinical Sales Representatives

Regional Sales Managers

Sales Representatives

Clinical Sales Representatives

SYMBOLPOSITION

U.S. Sales Force

• Endovascular intervention encompasses entire vascular system

• Saves thousands of lives and limbs using cutting-edge technologies

$11 Billion Dollar Industry

• Interventional Cardiologists

• Interventional Radiologists

• Vascular Surgeons

• Interventional Neuro-radiologists

• Interventional Nephrologists

Medical Specialties

Medical Facilities

Conducting procedures in over 3,000 facilities in the U.S.

Medical Facilities

And thousands more worldwide

Conducting procedures in over 3,000 facilities in the U.S.

• Aging population- Each day during the next 20 years approximately 13,000 people will turn 60 years old

• Technological advancements

• Increased adoptionof intervention

Growing Market

Vascular Disease and Intra-vascular Blood Clots in U.S. Patients

#1 Killer in America

Coronary Heart Disease: 2.6 millionPeripheral Vascular Disease (PVD): 2.5 million

Dialysis Treatment: 320,000

Neurologic Ischemia (stroke): 600,000

Pulmonary Embolism: 200,000

Narrowing of the artery causedby vascular disease (plaque)

-Plaque-Thrombus-Ischemia

Defining The Problem

Blood clot obstructsblood flow (Thrombus)

Narrowing of the artery causedby vascular disease (plaque)

-Plaque-Thrombus-Ischemia

Defining The Problem

Blood clot obstructsblood flow (Thrombus)

Endovascular interventionto restore blood flow

Narrowing of the artery causedby vascular disease (plaque)

-Plaque-Thrombus-Ischemia

Defining The Problem

The AngioJet System

Two components make up the AngioJet Ultra System

Ultra Console

Thrombectomy set

Core Technology

• 31 U.S. patents

• 6 Non-U.S. patents

• 25 U.S. patent applications

• 35 Non-U.S. patent applications

• Considerable portfolio of trade secrets

Strong Proprietary Protection

• Largest provider of mechanical thrombectomy

• Most advanced endovascular therapy for treatingintra-vascular blood clots

• FDA Indications for Coronary, Peripheral Arterial, Peripheral Venous and AV Access use

• DRG and CPT (reimbursement) codes for all four markets

Mechanical Thrombectomy Leader

Market Leader

328,000 patients treated

Cumulative Catheters Sold

6,538 15,23831,196

56,586

89,993

132,610

184,582

233,859

280,640

327,981

FY98 FY99 FY00 FY01 FY02 FY03 FY04 FY05 FY06 FY07

Lab Penetration

• Over 2,100 AngioJet® Systems placed worldwide• Used in 95% of largest U.S. coronary labs

Drive Units Placed

1,822

2,144

1,6451,465

1,210

863

669

443300

191

FY98 FY99 FY00 FY01 FY02 FY03 FY04 FY05 FY06 FY07First Gen Ultra

> 244 Ultra

• Robust business model fueled by a gross profit margin of 70 percent

• Non-GAAP (excl. Stock based comp.) profitability for 26 consecutive quarters

• Strong balance sheet with $43 million in cash and cash equivalents and no long-term debt

Financial Strength

1952-1960 Private, Industrial Products

1960-1976 Public, Industrial Products

1976-1993 Industrial & Medical Products

1994-2001 Development Stage Medical Products

2002-2004 Profitable, High Growth Mechanical Thrombectomy

2005-2006 Profitable, Clinical Study Impacts Coronary Growth

Our Future Return to High Growth, Endovascular Treatment

History

AiMI Study-Valuation Impacting Event

2006Fourth Quarter Employees Meeting

August 2004

A study designed for market expansion created a falseperception:

-AngioJet less effective than standard therapy in treating STEMI patients

-New safety concern with AngioJet in treating STEMI patients

AiMI- Likely An Anomaly

• Recently published real-world experience further confirms safety and efficacy of AngioJet thrombectomy for coronary use

• AiMI study control an anomaly

Journal of Invasive Cardiology

– July 2006

2006 JIC Supplement Outcomes

Confidence in Strength

Dedicated People Dedicated People Core Technology Core Technology

FDA Approved ProductsFDA Approved ProductsFinancial StabilityFinancial Stability

The strengths of Possis are focused on thrombus management and endovascular treatment products

Enduring Two Years

2006Fourth Quarter Employees Meeting

The Good,The Bad and

The UGLY

• Coronary sales declined 40 percent from peak in fiscal 2004

• Turnover of 45 percent in sales personnel

• Revenue declined to $62 mil. in fiscal 2006 vs. $72 mil. in fiscal 2004

• Non-GAAP (excl. stock based comp.) pre-tax income declined to $6 mil. in fiscal 2006 vs. $18.8 mil. in fiscal 2004

• Stock price declined from high of $34 per share to under $8 per share

The Bad and The Ugly

• Stabilized coronary sales; JIC publication shows AngioJet therapy safe and effective and finds AiMI study control to be an anomaly

• Invested heavily in new products and product labeling: DVX, XMI-RX+, Spiroflex, Spiroflex VG, GuardDog, Fetch, Venous FDA clearance, ULTRA

• Doubled peripheral product sales

• Introduced SafeSeal™ Hemostasis Patch into $45 mil. access site hemostasis market

• Generated new clinical science and intiated new studies; Dr. Sianos, JETSTENT, STEMI meta-analysis and PEARL registry

The Good

• Maintained firm pricing, maintained gross profit margin low to mid 70 percent and remained profitable

• Expanded placed drive units from 1465 in fiscal 2004 to 1822 in fiscal 2006

• Revitalized and strengthened our US sales force

• Secured CPT code reimbursement for AngioJet use in peripheral arteries and veins

• Cash and cash equivalents remained strong at $48 mil. in fiscal 2006 vs. $48 mil. in fiscal 2004 while repurchasing $27.2mil. in Possis stock and investing heavily in R&D

The Good

Possis Valuation History

2.5x1.5x2.4x6.5xEV / Revenue

$186$95$158$474Entity Value (EV)

$229$143$203$522Market Cap.

16.917.117.318.3 Shares Outstanding

$13.53$8.36$11.70$28.60Market Price Per Share

2007200620052004

Sept. 19,July 31st

Note:

A) Shares, market cap, and EV in millions

B) EV = market cap – cash + debt

Entity Value (EV) Multiple*Comparable Vascular Companies

2.54.8

3.1 3.0 3.73.62.0

5.2

0.02.04.06.08.0

EV3

Kense

y Nas

h

Spectr

aneti

cs

Vascu

lar Solu

tions

Fox H

ollow

Group M

ean (

5 c...

Small C

ap C

ardio.

..

Possis

EV

/LTM

Rev

enue

*Multiple of calendar 2007 revenue est.

(Unte

rberg’

s 24 c

os.)

Main

To be the worldwide leader in theendovascular treatment of intra-vascular thrombus and to be positioned to take

advantage of new opportunitiesbeyond this core business.

Vision

1. Increase adoption of AngioJet thrombectomy in our current mechanical thrombectomy markets(Coronary, PAO, AV Access)

Growth Strategies

Mechanical Thrombectomy Products

Realizable Market

Fiscal Year 2007

U.S. Market -- $440 mil.

AV AccessCoronary

Peripheral

Arterial

Possis leads with ~14% penetration

Majority of market remains untapped

Key Drivers:1. New and improved thrombectomy catheters

that improve performance and address unmet clinical needs

2. Improve AngioJet System ease-of-use

3. Provide increasingly compelling and current clinical data

4. Ensure appropriate reimbursement

Increasing AngioJet Adoption

Recent New Products Driving Adoption

Spiroflex® -PAO & Coronary

Spiroflex® VG-PAO & Coronary

Power Pulse™

Delivery

DVX®

AngioJet ULTRA Debuting in FY2007

Ultra Console

Thrombectomy Set(Catheter and pump)

FDA Approved and Full Market Launch!

• International JETSTENT study: a multi-center, prospective, randomized trial of AngioJet thrombectomy (200 patients enrolled)

• STEMI Meta-analysis of clinical outcomes following AngioJet treatment of thrombosed STEMI lesions

• PEARL registry; prospective, multi-center registry of Xpeedior & DVX catheters in real world (100+ patients enrolled)

• Dr. Sianos’s Thorax Centre study of AngioJet treatment prior to DES implantation ( JACC August 2007)

Ongoing & New Clinical Research

2006 JIC Supplement Detail

2006 JIC Supplement Detail

• Drug-eluting stent (DES) thrombosis is an ongoing, prominent concern in interventional cardiology

• Recent announcements from large DES manufacturer confirms higher rates of late DES thrombosis

• U.S. usage rate of DES has dropped from 90% to 60% of all stents

• Physicians focused on reducing risk

Drug-Eluting Stent (DES) Thrombosis

AngioJet Reduces Stent Thrombosis

Clinical research from The Thoraxcentre shows AngioJet Thrombectomy reduces incidence of DES thrombosis

No rheolytic thrombectomy

Rheolytic thrombectomy

P=0.011

8%11%

0%

Five new CPT codes provide for physician reimbursement of peripheral thrombectomy (arterial and venous)(January, 2006)

From $227 to $393 per treatment.

New Peripheral Reimbursements

1. Increase adoption of AngioJet thrombectomy in our current mechanical thrombectomy markets(Coronary, PAO, AV Access)

2. Expand AngioJet thrombectomyinto new markets (DVT, PE, Neurovascular)

Growth Strategies

Deep Vein Thrombosis (DVT)

• Currently U.S. market opportunity ~$90 million (60,000 procedures)

• Market penetration and growth require change in practice patterns (Anticoagulation Intervention)

• FDA indication and clinical science needed to fully capitalize on DVT market opportunity

-Venous 510(k) clearance received late November

Deep Vein Thrombosis (DVT)

• Currently estimate U.S. market opportunity to be ~$45 million (30,000 procedures)

• Market penetration and growth require change in practice patterns (Anticoagulation Intervention)

• FDA indication and clinical science needed to fully capitalize on PE market opportunity

Pulmonary Embolism (PE)

Expanding Opportunity

AngioJet Thrombectomy –More Market Segments – Larger Overall Opportunity

Fiscal Year 2007U.S. Market -- $440 mil.

AV AccessCoronary

Peripheral

Arterial

Fiscal Year 2010U.S. Market -- $675 mil.

AV AccessCoronary

Peripheral

ArterialPulmonary

Embolism

Deep Vein

Thrombosis

1. Increase adoption of AngioJet thrombectomy in our current mechanical thrombectomy markets (Coronary, PAO, AV Access)

2. Expand AngioJet thrombectomyinto new markets (DVT, PE, Neurovascular)

3. Market a growing catalog of thrombus management and other endovascular productsto our established customer network by leveraging our enterprisestrengths

Growth Strategies

• Established, effective distribution channel

• Regulatory competency and track record

• Medical device engineering and manufacturing expertise

• Active, expanding customer network (nearly 1800 sites)

• Brand recognition and marketplace credibility

• Robust business model and strong cash position

Growth Strategies

Leverage the Strengths of Our Enterprise

Thrombus Management• Adjunctive products to support AngioJet use

• Other thrombus management products that provide additional value

Growth Strategies

Key areas of focus:

Thrombus Management• Adjunctive products to support AngioJet use

• Other thrombus management products that provide additional value

Other Endovascular Products• New and/or underserved markets

• Capitalize on relationships and expertise of sales force

Growth Strategies

Key areas of focus:

Thrombus Management Products

GuardDOG® Occlusion System-restarted beta-launch of GD withimproved joint in Q4

Thrombus Management Products

FETCH™ Aspiration Catheter- full market release with increasing sales

• $2.5 mil. investment with option to acquire Rafael Medical

• Current market >$170 mil. $200 mil. + by 2010

• Currently under clinical study for 510(k) clearance

Thrombus Management Products

SafeFlo® IVC Filter

SafeFlo®

Retrievable IVC Filter

I.V.C Filter

Inferior Vena Cava (IVC)Carries de-oxygenated blood from lower body to heart

IVC filter:Protect against embolization of thrombus from leg veins (DVT) causing pulmonary embolism (PE)

Two types of filters:• Permanent• Retrievable (SafeFlo)

The Role of an IVC Filter

• Current market >$45 mil.

• Product developed via partnership with Medafor, Inc.

• Introduced in June 2006

New Endovascular Products

SafeSeal™ Hemostasis Patch

New Endovascular Ventures

Chronic Total Occlusion (CTO)• Waterjet enhanced CTO wire• $500 mil. opportunity by 2010

Atherectomy• Waterjet technology to aid atherectomycutting and expedite complete debrisremoval

• $650 mil. opportunity by 2010

Two Products in early R&D phase:

Combined Market Opportunity

U.S Realizable Endovascular Treatment Market Opportunity

AngioJetThrombectomy

Adjunctive Thrombus Management

New Endovascular Treatments

2010 Estimate -- $2.31 billion

$675 m$440 m

$385 m

$1.25 b

$290 m

2007 Estimate -- $790 million

$60 m

1. Increase adoption of AngioJet thrombectomy in our current mechanical thrombectomy markets(Coronary, PAO, AV Access)

2. Expand AngioJet thrombectomyinto new markets (DVT, PE, Neurovascular)

3. Market a growing catalog of thrombus management and other endovascular productsto our established customer network by leveraging our enterprisestrengths

4. Continue worldwide expansion(Europe)

Growth Strategies

• Focus on AngioJet thrombectomy in select markets where opportunity justifies investment

• Leverage recent investments in European clinical research in current and new markets (ie., pulmonary embolism)

• New thrombus management and endovascular products may justify additional investment

Continued Worldwide Expansion

• Product pipeline is full

• Product portfolio includes non-AngioJet products

• New, positive clinical science

• Venous clearance

• Favorable reimbursement

• GPO contracts in place

• Financial strength

• Revitalized and strengthened sales force

• Robust business model

• Easing financial performance comparables

• Growth Plan in place

Stronger Today

An Evolving Investment Story

Development Development High Growth High Growth

Damaged GoodsDamaged GoodsGrowth RecoveryGrowth Recovery

Possis is on the cusp of returning to high growth where plan execution is key.

• 4th qtr. revenue increased 18 percent vs. prior year -and 17 percent sequentially

• Coronary grew 2 percent vs. 4th qtr. last year; first yr. over yr. increase in 12 quarters

• Double-digit sequential coronary, peripheral, and AV growth in 4th qtr.

• Growth driven by new AngioJet Ultra System; catheter usage up 30+ percent so far…

• Generated $2.6 million of positive operating cash flow

4th Qtr. Fiscal 2007 Results

1st Qtr. 2nd Qtr. 3rd Qtr. 4th Qtr.

Revenue (mil.) $15.6 $15.8 $16.2 $19.0

Gross Profit Margin 71.7% 70.0% 68.0% 68.4%

Non-GAAP EPS $0.02 $0.05 $.05 $.03

EPS ($0.01) $0.01 $.00 $.00

Note: Met guidance Q1 & Q2, missed in Q3, exceeded guidance in Q4; four qtrs. sequential & year-over-year quarterly revenue growth.

Fiscal 2007 Highlights

2008 Guidance

12+ Percent Growth

Revenue ($)

$42.5

$57.4

$72.4$65.1 $61.9

$75 est.

$66.7

FY02 FY03 FY04 FY05 FY06 FY07 FY08

$'s Millions

$ 65 $ 75

$ 62

$ 72

$ 67

$4 0

$4 5

$50

$55$6 0

$6 5

$70

$75

$8 0

F iscal 2 0 0 4 A ct ual F iscal 2 0 0 5 A ct ual F iscal 2 0 0 6 A ct ual F iscal 2 0 0 7 A ct ual F iscal 2 0 0 8 Guid ance

Rev

enue

($) M

illion

s

$-$5

$10$15$20$25$30$35$40

Fiscal 2004 Fiscal 2005 Fiscal 2006 Fiscal 2007 Fiscal 2008 YTD

Stock Range (Fiscal Year 2004 - 2008 YTD)

Stoc

k Pr

ice

($) $34.15

$15.01

$30.76

$8.02 $13.39$7.71 $8.28

$14.19

Return To Growth-Comparables Improving

$13.66$9.55

Improving Lives

Thank You !